Investigation of the relationship between ischemic stroke and endothelial nitric oxide synthase gene polymorphisms [G894T, intron 4 VNTR and T786C]

Süleyman Ömer ANLIAÇIK 1, Serhat TOKGÖZ 1,*, Ayşe Gül ZAMANI 2, Mahmut Selman YILDIRIM 3, Mehmet Sinan İYİSOY 3

1Department of Neurology, Meram Medical Faculty, Necmettin Erbakan University, Konya, Turkey
2Department of Molecular Biology and Genetics, Meram Medical Faculty, Necmettin Erbakan University, Konya, Turkey
3Department of Medical Education and Informatics, Meram Medical Faculty, Necmettin Erbakan University, Konya, Turkey

Received: 13.08.2018 • Accepted/Published Online: 17.02.2019 • Final Version: 18.04.2019

1. Introduction
According to the WHO, stroke is a clinical syndrome caused by vascular lesion. It is characterized by rapidly occurring clinical symptoms and/or signs of focal or generalized cerebral dysfunction lasting more than 24 h or resulting in death [1].

Despite improvements in the treatment of acute stroke, strokes continue to represent the third-leading cause of death in many countries. Therefore, identification and prevention of stroke risk factors are gaining increasing importance. Approximately 70% of stroke risk is attributed to known etiological risk factors, and genetic factors may account for a significant proportion among the remaining unidentified causes [2].

Polymorphisms affecting various genes, such as angiotensin converting enzyme (ACE), thrombin-activatable fibrinolysis inhibitor (TAFI), and nitric oxide synthase (NOS) genes, as suggested by recent advances in genetic research techniques are associated with the incidence of ischemic stroke (3–9). Nitric oxide (NO), an enzyme that regulates the endothelial microenvironment by reducing intracellular calcium levels, inhibits platelet aggregation and vascular smooth muscle cell proliferation, and reduces leukocyte adhesion [4,10].

The enzyme NOS catalyzes a reaction whereby L-arginine is synthesized from the N-terminus of guanidine. There are two forms of NOS: constitutive and inducible. Different genes synthesize different forms of NOS [NOS1 (neuronal NOS), NOS2, and NOS3 (endothelial NOS)] enzymes [11]. The NOS also inhibits the oxidation of low-density lipoprotein, thereby regulating the endothelial microenvironment [4,10]. Thus, any genetic problem disrupting the amount and structure of NO will cause an inclination towards clotting.

In some populations, although a significant relationship was found between the risk of ischemic stroke...
and the polymorphisms of the endothelial NOS (eNOS) gene (G894T, VNTR, T786C, etc.), studies to determine whether it may be a risk factor have delivered conflicting results. Studies in different populations with various polymorphisms may help determine the risk of stroke in those populations. We therefore aimed to determine whether there are significant differences in the G894T [rs1799983], intron 4 [27-bp TR] VNTR, and T786C [rs2070744] polymorphisms of the eNOS gene between stroke patients and healthy individuals in the central Anatolian population.

2. Materials and methods

2.1. Identification of cases, inclusion and exclusion criteria
To investigate whether there are significant differences in the distributional frequencies of the G894T (rs1799983), intron 4 (27-bp TR) VNTR, and T786C (rs2070744) polymorphisms of eNOS in the central Anatolian population, we designed two groups: healthy individuals (control group) and adult stroke patients aged > 18 years. We included 272 individuals (112 patients and 160 controls) in the study. Individuals without a history of ischemic stroke were included in the control group. Patients with ischemic stroke were classified according to the Trial of Org 10172 in acute stroke treatment (TOAST) classification system, and those with “stroke of undetermined etiology” and without any of the exclusion criteria were included in the patient group. The exclusion criteria are listed in Figure. We collected blood samples from the control and the patient groups upon their admission to the neurology outpatient clinic or emergency department of our hospital.

We recorded demographic information including age, sex, medical history, and risk factors for stroke such as hypertension, coronary artery disease, diabetes, hyperlipidemia (Table 1). Blood samples obtained from the patients and the control groups were stored at −80 °C and subsequently subjected to genetic analysis.

2.2. DNA isolation
We isolated genomic DNA from the blood samples using the DNA isolation kit (DNAeasy Blood & Tissue Kit, Qiagen GmbH, Hilden, Germany). We checked the purity and quantity of the extracted DNA by measuring the absorbance at 260 nm and 280 nm using a spectrophotometer (Nano Drops spectrophotometer, Thermo Scientific, USA).

2.3. Real-time polymerase chain reaction (RT-PCR) stage
We performed real-time PCR using fluorescence-labeled TaqMan probes specific for the eNOS G894T [rs1799983], intron 4 (27-bp TR) VNTR, and T786C (rs2070744) polymorphisms. We mixed the hybridization solution (Taq polymerase, reaction buffer, and nucleotide mix), MgCl₂, primers, and probes and genomic DNA so as to obtain a total volume of 20 μL and transferred them to a real-time PCR device. We also used positive and negative controls. After completion of the real-time PCR amplification, we generated melting curves and then genotyped eNOS G894T (rs1799983), intron 4 (27-bp TR) VNTR, and T786C (rs2070744) polymorphisms using an allelic discrimination assay.

2.4. Statistical analysis
We performed statistical analyses using the SPSS 15.0 (SPSS Inc., Chicago, IL, USA). We determined the mean and standard deviations of the continuous variables.

![Image of the flowchart](image-url)
and the frequencies and percentages of the categorical variables. We used the chi-square and Fisher's exact test for intergroup comparisons of categorical variables. We used binary logistic regression analysis to compare the frequencies of alleles among the patient and control groups. We used the wild type (of genotypes and alleles) as a reference for regression analysis. P ≤ 0.05 was considered statistically significant.

3. Results
The mean age was 68.58 (± 10.848) years in the patient group and 61.44 (± 8.104) years in the control group. The patient group comprised 50 (44.6%) females and 62 (55.4%) males, whereas the control group comprised 95 (59.4%) females and 65 (40.6%) males. The demographic properties and risk factors of the patients have been presented in Table 1.

3.1. G894T polymorphism
Table 2 presents the genotypes and allele frequencies. The differences in both genotypes and T alleles were not statistically significant between the patient and control groups (Table 2).

3.2. Intron 4 (27-bpTR) VNTR (4b/a) polymorphism
The 4b/a (heterozygous polymorphism) and 4a/a (homozygous polymorphism) genotypes as well as the

Table 1. Demographic data and the risk factors in patient and control groups.

|                          | Patient [n, %] | Control [n, %] | P     | χ²  |
|--------------------------|---------------|---------------|-------|-----|
| Age [mean, standard deviation] | 68.58 [± 10.848] | 61.44 [± 8.104] | < 0.05 | 85.810 |
| Gender                   |               |               |       |     |
| Male                     | 62 [55.4%]    | 65 [40.6%]    | < 0.05 | 6.779 |
| Female                   | 50 [44.6%]    | 95 [59.4%]    | < 0.05 | 6.779 |
| Diabetes mellitus        | 40 [35.7%]    | 33 [20.6%]    | < 0.05 | 8.011 |
| Hypertension             | 61 [54.5%]    | 47 [29.4%]    | < 0.05 | 15.785 |
| Coronary artery disease  | 15 [13.4%]    | 47 [29.4%]    | < 0.05 | 11.321 |
| Smoke                    | 9 [8%]        | 15 [9.4%]     | NS    | 1.159 |
| Hyperlipidemia           | 32 [28.6%]    | 19 [11.9%]    | NS    | 2.449 |

NS: Nonsignificant

Table 2. Genotype distributions of eNOS G894T [rs1799983], intron 4 [27-bpTR] VNTR, eNOS T786C polymorphisms, and allelic frequencies in the patient and control groups [binary logistic analysis, wild type is reference for statistical analysis].

| Polymorphism   | Genotype | Patient [n, %] | Control [n, %] | P     | OR   | 95% CI    |
|----------------|----------|---------------|---------------|-------|------|-----------|
| G894T [rs1799983] | GG       | 21 [%18.8]    | 38 [%23.8]    | -     | 1    |           |
|                | GT       | 77 [%68.8]    | 103 [%64.4]   | 0.262 | 1.440 (0.76-2.77) |
|                | TT       | 14 [%12.5]    | 19 [%11.9]    | 0.561 | 1.313 (0.52-3.29) |
| Allele         | G        | 115 [%39.1]   | 179 [%60.9]   | -     | 1    |           |
|                | T        | 109 [%43.8]   | 140 [%56.2]   | 0.272 | 1.211 (0.86-1.70) |
| intron4 VNTR   | 4b/b     | 57 [%50.9]    | 124 [%77.5]   | -     | 1    |           |
|                | 4b/a     | 50 [%44.6]    | 34 [%21.3]    | < 0.0001* | 3.396 (1.93-6.08) |
|                | 4a/a     | 5 [%4.5]      | 2 [%1.3]      | 0.016* | 10.631 (1.51-215.9) |
| Allele         | b        | 164 [%36.8]   | 282 [%63.2]   | -     | 1    |           |
|                | a        | 60 [%61.2]    | 38 [%38.7]    | < 0.0001* | 2.715 (1.73-4.26) |
| T786C          | TT       | 59 [%52.7]    | 38 [%23.8]    | -     | 1    |           |
|                | TC       | 35 [%31.2]    | 103 [%64.4]   | < 0.0001** | 0.244 (0.13-0.44) |
|                | CC       | 18 [%16.1]    | 19 [%11.9]    | 0.314 | 0.663 (0.30-1.48) |
| Allele         | T        | 152 [%45.92]  | 179 [%54.07]  | -     | 1    |           |
|                | C        | 72 [%33.96]   | 140 [%66.03]  | 0.006** | 0.605 (0.42-0.86) |

*The frequency of 4b/a, 4a/a genotypes and a allele were significantly higher in the patient group than the control group.

**The frequencies of TC genotype and C allele were significantly lower rate in the patient group than the control group.
a alleles were significantly higher in the patient group than in the control group (OR: 2.715, 95% CI: 1.73–4.26, P < 0.001; OR: 3.396, 95% CI: 1.93–6.08, P < 0.001; OR: 10.631, 95% CI: 1.51–215.89, P = 0.016, respectively) (Table 2).

### 3.3. T-786C polymorphism

Table 3 also presented the results of the binary logistic regression analysis. Unlike the first two polymorphisms, the wild type genotype and allele (TT and T) were found to be higher in the patient group than in the control group. The TC genotype and C alleles of the T786C (rs2070744) polymorphism was significantly less frequent in the patient group than in the control group (OR: 0.244, 95% CI: 0.13–0.44, P < 0.001; OR: 0.605, 95% CI: 0.42–0.86, P = 0.006, respectively) (Table 2).

### 4. Discussion

Some studies on eNOS gene polymorphisms (including G894T, VNTR, and T786C) have suggested that, in some populations, eNOS is a risk factor for ischemic stroke; however, few conflicting results have also been reported [3,4,6,9,10,12–16]. Polymorphisms may play a specific penetrating role for ethnicity in the sensitivity of ischemic stroke. We investigated the existence of a relationship between the G894T (rs1799983), VNTR (4b/a), and T786C (rs2070744) polymorphisms of the eNOS gene and ischemic stroke in the central Anatolian population.

#### 4.1. T-786C polymorphism

According to some metaanalyses, no significant differences exist between the Asian and Caucasian populations in terms of the T786C genotypes and allele distributions (Table 3) [6,10]. However, in a contrasting metaanalysis reported by Wang et al. [17], the predominance of the C allele of the T-786C polymorphism was highlighted in Asians, indicating a significant protective effect against the risk of ischemic stroke in the codominant models (C vs T for T-786C) (Table 3) [17]. In our study, we also observed that the C alleles and TC heterozygote polymorphism genotype were significantly lower in the patient group (with the possibility of a protective effect) in the Anatolian population (Tables 2 and 3).

#### 4.2. G894T polymorphism

A significant relationship between the T allele and TT genotype of the G894T polymorphism and ischemic stroke risk was found in Asians and north Indians, but not in Caucasians (Table 4) (3,6,10,17,18). In Morocco, Diakite et al. reported a significant relationship between the G894T eNOS polymorphism and ischemic stroke in recessive, dominant, and codominant models (Table 5) [16].

In a study conducted by Guldiken et al. [19], the difference in the allelic frequency and genotypic distribution of the G894T (rs1799983) polymorphism between the ischemic stroke and the control group in the Anatolian population was not statistically significant (Table 4) [19]. This result was similar to our results in the Anatolian population (Table 4).

#### 4.3. Intron 4 (27-bpTR) VNTR (4b/a)

Some studies have reported a significant relationship between ischemic stroke and the 4a/a genotype and/or the 4a allele of intron 4 (27-bpTR) VNTR polymorphism of the eNOS gene in South India and among the Asian population, but not in the Caucasian population (Table 5) [4,6,10,17].

Wang et al. reported a significant relationship between the 4a allele and the risk of ischemic stroke in dominant and codominant models in the Chinese population (Table 5) [17].

Yemişçi et al. [20] suggested that, in the Anatolian population, the 4a/a genotype is protective for isolated symptomatic lacunar infarction, and this effect is enhanced in the absence of the T786C polymorphism in the promoter region. On the contrary, in our study, the frequency of the 4 a/a and 4b/a genotypes and alleles were higher in the patient group than in the control group, and

| Genotype | Allele | Country (Ethnicity) |
|----------|--------|---------------------|
| TT       | TC     | CC                  |
| Yao YS et al. | NS | NS | NS | NS | Asian, Caucasian |
| Guo X | NS | NS | NS | NS | Asian, Caucasian |
| Wang M et al. | NS | P < 0.05 * | NS | NS | Asian |
| Our study | NS | < 0.0001* | NS | 0.006* | Anatolian |

NS: Statistically nonsignificant result. TT, TC, CC: Genotypes of eNOS T786C polymorphism. T and C: Alleles of eNOS T786C polymorphism.

*The frequency of TC genotype and C allele were significantly lower rate in the patient group than the control group (protective effect?).
this difference was highly statistically significant. This contrasting result may be attributed to the inclusion of only the lacunar infarction group by Yemisci et al. (Table 5) [20].

Our study is limited by the absence of the evaluation of body mass index and cholesterol subtypes of patients. According to the TOAST classification, the incidence of stroke with an unknown cause is 25%–39% [20]. We selected only a specific subset of patients and excluded other causes of stroke, such as atrial fibrillation and we couldn't add some important polymorphisms such as factor V and prothrombin gene polymorphisms for analysis, because they are not routinely available in our laboratory.

In conclusion, this is the first study on the eNOS T786C polymorphism and the second study on the G894T [rs1799983] and intron 4 VTNR [4a/a] gene polymorphisms in the Anatolian population. While no significant relationship exists between the T786C polymorphism and stroke in Asians and Caucasians,
we found a significantly low frequency of the T786C polymorphism (which has a protective effect) in Anatolian stroke patients, which is similar to that reported by Wang et al [17]. Guldiken et al. [19], too, found no relationship between the eNOS G894T [rs1799983] gene polymorphism and stroke risk in the Anatolian population compared with the Asian population. We also detected a highly significant increase in the intron 4 VNTR gene polymorphism in the stroke patients compared with the Caucasian population.

On this basis, further studies of the normal function of NO are warranted in terms of primary and secondary protection against ischemic stroke.

Acknowledgements

The study was approved by the local ethic committee of Meram Medical Faculty, Ethic approval code: 2015/396. All participants provided informed consent in the format required by the relevant authorities and/or boards.

References

1. Sudlow CL, Warlow CP. Comparing stroke incidence worldwide what makes studies comparable? Stroke 1996; 27 (3): 550-558. doi.org/10.1016/0161-3052.3.550
2. Boehme AK, Esenwa C, Elkind MS. Stroke risk factors, genetics, and prevention. Circulation Research 2017; 120 (3): 472-495. doi: 10.1161/CIRCRESAHA.116.308398.
3. Tao HM, Chen GZ. Endothelial NO synthase gene polymorphisms and risk of ischemic stroke: a meta-analysis. Neuroscience Research 2009; 64 (3): 311-316. doi: 10.1016/j.neures.2009.04.001
4. Munshi A, Rajeshwar K, Kaul S, Chandana E, Shaft G et al. VNTR polymorphism in intron 4 of the eNOS gene and the risk of ischemic stroke in a South Indian population. Brain Research Bulletin 2010, 82 (5-6): 247-250. doi: 10.1016/j.brainresbull.2010.05.008
5. Ladenvall C, Gils A, Jood K, Blomstrand C, Declerck PJ et al. Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation. Arteriosclerosis, Thrombosis, and Vascular Biology 2007; 27 (4): 955-962. doi:10.1161/01.ATV.0000259354.93789.
6. Guo X. Endothelial nitric oxide [eNOS] gene G894T and VNTR polymorphisms are closely associated with the risk of ischemic stroke development for Asians: meta-analysis of epidemiological studies. Molecular Biology Reports 2014; 41 (4): 2571-2583. doi: 10.1007/s10728-014-2115-8
7. Tokgoz S, Zamani AG, Durakbasi-Dursun HG, Yilmaz O, Ilhan N et al. TAFI gene polymorphisms in patients with cerebral venous thrombosis. Acta Neurologica Belgica 2013; 113: 291-297. doi: 10.1007/s13760-012-0170-6
8. WeiLK, Au A, Menon S, Griffiths LR, Kooi CW et al. Polymorphisms of MTHFR, eNOS, ACE, AGT, ApoE, PON1, PDE4D, and ischemic stroke: Meta-analysis. J Stroke Cerebrovasc Dis 2017; 26 (11): 2482-2493. doi: 10.1016/j.jstrokecerebrovasdis.2017.05.048.
9. Kang MK, Kim OJ, Jeon YJ, Kim HS, Oh SH et al. Interplay between polymorphisms in the endothelial nitric oxide synthase [eNOS] gene and metabolic syndrome in determining the risk of ischemic stroke in Koreans. Journal of the Neurological Sciences 2014; 344 (1): 55-59. doi: 10.1016/j.jns.2014.06.020
10. Yao YS, Chang WW, Jin YL, He LP. An updated meta-analysis of endothelial nitric oxide synthase gene: three well-characterized polymorphisms with ischemic stroke. Gene 2013; 528 (2): 84-92. doi: 10.1016/j.gene.2013.06.047.
11. Sawada T, Kishimoto T, Osaki Y, Okamoto, M, Tahara A et al. Relation of the Glu298Asp polymorphism of the nitric oxide synthase gene to hypertension and serum cholesterol in Japanese workers. Preventive Medicine 2008; 47 (2): 167-171. doi: 10.1016/j.ypmed.2008.04.006.
12. Chen ZQ, Mou RT, Feng DX, Wang Z, Chen G. The role of nitric oxide in stroke. Medical Gas Research 2017; 7 (3): 194-203. doi: 10.4103/2045-9912.215750
13. Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, controls. Cell 1994; 78 (6): 915-918. doi: 10.1002/0092-8674(94)90266-6
14. Djordjevic V, Stankovic M, Brankovic-Streckovic V, Rakicevic L, Radojkovic D. Genetic risk factors for arterial ischemic stroke in children: a possible mthfr and enos gene-gene interplay? Journal of Child Neurology 2009; 24 (7): 823-827. doi: 10.1177/0883073808330164.
15. Song J, Kim OJ, Kim HS, Bae SJ, Hong SP et al. Endothelial nitric oxide synthase gene polymorphisms and the risk of silent brain infarction. International Journal of Molecular Medicine 2010; 25 (5): 819-823. doi: 10.3892/ijmm_00000410
16. Diakite B, Hamzi K, Slassi I, El Yahyaoui M, El Alaoui MM et al. G894T endothelial nitric oxide synthase polymorphism and ischemic stroke in Morocco. Meta Gene 2014; 7: 349-357. doi: 10.1016/j.mgene.2014.04.003
17. Wang M, Jiang X, Wu W, Zhang D. Endothelial NO synthase gene polymorphisms and risk of ischemic stroke in Asian population: a meta-analysis. PLoS ONE 2013; 8 (3): e60472. doi: 10.1371/journal.pone.0060472
18. Kumar A, Misra S, Kumar P, Saqar R, Prasad K et al. Association between Endothelial nitric oxide synthase G894T gene polymorphism and risk of ischemic stroke in North Indian population: a case-control study. Neurological Research 2016; 38 (7): 575-579. doi: 10.1007/s11033-016-1181376
19. Guldiken B, Sipahi T, Guldiken S, Ustundag S, Budak M et al. Glu298Asp polymorphism of the endothelial nitric oxide synthase gene in Turkish patients with ischemic stroke. Molecular Biology Reports 2008; 36 (6): 1539-1543. doi: 10.1007/s11033-008-9348-7
20. Yemişçi M, Sinici I, Özkara HA, Hayran M, Ay H et al. Protective role of 27bp repeat polymorphism in intron 4 of eNOS gene in lacunar infarction. Free Radical Research 2009; 43 (3): 272-279. doi: 10.1080/10715760802691489